Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Walter K Kraft
*Thomas Jefferson University, walter.kraft@jefferson.edu*

Kevin Dysart
*Jefferson Medical College*

Jay S Greenspan
*Jefferson Medical College*

Eric Gibson
*Jefferson Medical College*

Karol Kaltenbach
*Jefferson Medical College*

See next page for additional authors

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/petfp](http://jdc.jefferson.edu/petfp)

Part of the [Medical Pharmacology Commons](http://jdc.jefferson.edu/petfp)

Recommended Citation

Kraft, Walter K; Dysart, Kevin; Greenspan, Jay S; Gibson, Eric; Kaltenbach, Karol; and Ehrlich, Michelle E, "Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome." (2011). *Department of Pharmacology and Experimental Therapeutics Faculty Papers*. Paper 7.

[http://jdc.jefferson.edu/petfp/7](http://jdc.jefferson.edu/petfp/7)
Revised Dose Schema of Sublingual Buprenorphine in the Treatment of the Neonatal Opioid Abstinence Syndrome

Volume 106, Issue 3, March 2011, Pages 574-580

DOI: 10.1111/j.1360-0443.2010.03170.x

Walter K. Kraft* M.D., Kevin Dysart♦ M.D., Jay S. Greenspan♦ M.D., Eric Gibson♦ M.D., Karol Kaltenbach* Ph.D., Michelle E. Ehrlichγ M.D.

Jefferson Medical College, Philadelphia
Departments of Pharmacology and Experimental Therapeutics*, and Pediatrics*

♦A.I. DuPont Hospital for Children, Wilmington, DE

γMt. Sinai School of Medicine, New York, NY, Departments of Pediatrics and Neurology

Corresponding Author:
Walter K. Kraft, M.D.
132 South 10th Street, 1170 Main Building
Phone- 215-955-9077; Fax- 215-955-5681
Walter.Kraft@jefferson.edu

The project described was supported by the Commonwealth of Pennsylvania Tobacco Fund and Grant Number R21DA018207 from the National Institute on Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health.

Word Count:
Abstract Word Count: 151
References:
Tables: 3
Figures: 2

Keywords (MeSH unique ID#): Neonatal Abstinence Syndrome (D009357), buprenorphine (D002047), Sublingual Drug Administration (D000286), morphine (D009020)

ClinicalTrials.gov Identifier # NCT00521248
ABSTRACT

AIMS: Over half of infants exposed to opioids in utero develop neonatal abstinence syndrome (NAS) of severity to require pharmacologic therapy. Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS.

DESIGN: Randomized, phase 1, open-label, active-control clinical trial comparing sublingual buprenorphine to oral morphine.

SETTING: Large, urban, tertiary care hospital.

PARTICIPANTS: Twenty-four term infants with signs and symptoms of NAS.

MEASUREMENTS: Outcomes were neonatal safety, length of treatment, and length of hospitalization.

FINDINGS: Sublingual buprenorphine was safe and effective. Infants treated with buprenorphine had a 23-day length of treatment compared to 38 days for those treated with morphine (p=0.01), representing a 40% reduction. Length of stay in the buprenorphine group was reduced 24%, from 42 to 32 days (p=0.05).

CONCLUSIONS: Sublingual buprenorphine was safe in NAS, with a substantial efficacy advantage over standard of care therapy with oral morphine.
INTRODUCTION

Infants born to mothers receiving methadone maintenance often develop withdrawal symptoms in a complex known as the neonatal abstinence syndrome (NAS). NAS is characterized by signs and symptoms of CNS hyperirritability, gastrointestinal dysfunction, respiratory distress, and autonomic symptoms. (1) Common symptoms in order of frequency include tremors, high-pitched cry, sneezing, increased muscle tone, regurgitation and vomiting, poor sleep, loose stools, sweating, excoriation, mottling, nasal stuffiness, low-grade fever, and tachypnea. NAS reflects a spectrum of disease, and those with milder symptoms respond well to supportive treatments. (2) NAS symptoms severe enough to require pharmacologic treatment occur in 55-94% of infants born to opioid-dependent mothers. (1)

The optimal pharmacologic regimen for NAS has not been established, as reflected in the considerable heterogeneity in the diagnosis (3) and treatment of NAS among different institutions. (4,5) Treatments employed have included opioids, anticonvulsants, benzodiazepines, alpha 2 adrenergic antagonists, chloral hydrate, and the phenothiazine antipsychotic agent chlorpromazine. Cochrane reviews, (6,7) the American Academy of Pediatrics, (1) and expert review (8,9) identify opioid replacement as the ideal treatment for the withdrawal symptoms associated with in utero exposure to opiates. Morphine is the most commonly used agent, and is associated with treatment duration of 8-79 days, (10-15) almost always in an inpatient setting. The use of outpatient treatment in
highly selected patients has been reported to be associated with shorter inpatient stays, but longer total duration of therapy. (16)

Buprenorphine is a long-acting partial mu opioid receptor agonist used in the treatment of adult abstinence therapy. It has the advantage of decreased abuse potential and less respiratory depression than other opioid agonists. We have previously reported the first use of sublingual buprenorphine in NAS at a dose of 13.2 mcg/kg/day in three divided doses. (17) Though designed as a phase 1 safety study, the investigation suggested reduction in lengths of treatment and inpatient hospitalization of approximately 30%. A higher incidence of phenobarbital adjunctive therapy in the buprenorphine group led us to optimize dose parameters. We report here on a second cohort of 24 patients treated with this revised dose schema.

METHODS

Study Design

This was a single site, randomized, open label trial. (Figure 1) Neonates were randomized to treatment with either sublingual buprenorphine or oral morphine in a 1:1 ratio. NAS was graded using the MOTHER NAS score, which is the standard instrument used in the multicenter NIH funded MOTHER study (ClinTrials.gov ID NCT00271219) of buprenorphine in pregnancy. (18) It is also the standard instrument at TJUH. The MOTHER NAS score (hereafter “NAS score”) is based upon the Finnegan score, (19) modifications of which are the most commonly used to monitor NAS. (5,20) Initiation of treatment was based on
any consecutive 3 scores adding up to ≥ 24. Inclusion criteria included ≥ 37 weeks gestation, exposure to opioids in utero, and demonstration of signs and symptoms of NAS requiring treatment. Exclusion criteria were major congenital malformations and/or intrauterine growth retardation, (21) medical illness requiring intensification of medical therapy, concomitant maternal benzodiazepine or severe alcohol abuse, maternal use of alcohol or of benzodiazepines in the 30 days prior to enrollment (as determined by self-report or intake urine drug screen), concomitant neonatal use of cytochrome P450 3A inhibitors or inducers prior to treatment, seizure activity or other neurologic abnormality, breast feeding or inability of mother to give informed consent due to co-morbid psychiatric diagnosis. The study was approved by the Institutional Review Board of Thomas Jefferson University. Computer-generated randomization was performed by the hospital Investigational Drug Service.

Study Treatments

Patients randomized to sublingual buprenorphine initially received 15.9 mcg/kg/day in 3 divided doses. Buprenorphine solution was prepared by mixing buprenorphine for injection (Buprenex, Reckitt Benckiser) to a final concentration of 0.075 mg/mL in 100% ethanol USP (30% of total volume) and simple syrup USP (85 gm sucrose/100 ml). The solution was administered under the tongue followed by insertion of a pacifier to reduce swallowing. Dose escalation was a 25% increase for NAS scale scores ≥24 total on 3 measures or a single score of ≥12. Patients with inadequate control could be administered a rescue dose of
50% of the previous dose, after which the subsequent dose would be advanced 25%. After at least 3 days of dose stabilization, patients could begin weaning for scores < 8. Weaning was at intervals of 10%. Cessation of dosing occurred when buprenorphine was within 10% of the initial dose. All dose calculations were based upon birth weight. If NAS was not controlled with maximally specified dose of 60 mcg/kg/day, patients were administered phenobarbital 20 mg/kg load followed by 2.5 mg/kg twice a day for at least 2 days. Phenobarbital was weaned prior to reduction of the opioid. When NAS scores were reliably <8, the daily dose of phenobarbital was reduced by 50%, followed by complete cessation.

Standard of care treatment at Thomas Jefferson University Hospital consisted of an initial dose of morphine 0.4 mg/kg/day in 6 divided doses with dose escalation of 10%/day for NAS scale scores ≥24 total on 3 measures or a single score of ≥12. All dose calculations were based upon daily weight. Adjunctive treatment with phenobarbital was initiated when the dose of morphine reached 1 mg/kg/day. Weaning from the phenobarbital was the same in both the buprenorphine and morphine groups. Infants were weaned with 10% dose reduction every 24 hours in morphine as tolerated until 0.15 mg/kg/day was reached. All patients in the trial were observed for at least two days following the cessation of dosing.

Statistics
This was a follow up pilot study to optimize the dose of sublingual buprenorphine in neonates. Therefore, sample size was not based upon a formal power calculation. Group comparisons for continuous variables were made using the Mann-Whitney U test. Statistical analysis was completed with JMP 5.1.2, (SAS Institute Inc.) Analysis was performed on an intention to treat basis.

RESULTS

Twenty-four infants were enrolled between March 2008 and January 2010. Patient characteristics are presented in Table 1.

Safety

A list of all adverse events observed in the trial is presented in Table 2. There was one serious adverse event in a patient randomized to buprenorphine. This infant randomized to buprenorphine had adverse events of CMV infection, prolonged reflux/poor feeding, elevated transaminases, aminoaciduria, and paronychia of a finger. Poor feeding and enteral hypomotility was initially thought to be part of NAS, but lack of resolution on buprenorphine and phenobarbital, and indeed no worsening when these drugs were removed led to further medical evaluation. CMV was noted in urine, and a lack of cerebral calcifications or microcephaly at birth suggest a late in utero or possibly nosocomial infection. Length of buprenorphine treatment was 45 days and length of stay was 98 days. On the last day of buprenorphine weaning, alanine transaminase (ALT) was
noted to be 30x the upper limit of normal (ULN), while aspartate transaminase (AST) was noted to be 20x ULN. These values waxed and waned over the remainder of the hospitalization, and remained elevated 6 weeks following the cessation of buprenorphine. Bilirubin was never elevated. The DSMB reviewed the case and came to the unanimous judgment that buprenorphine was not responsible for the clinical course of the infant, but did endorse our suggestion to monitor liver function for future enrollees. Liver function testing pre-dose, and at 7 and 21 days post randomization was normal in 6 subsequent patients (three in each treatment arm).

Efficacy

Infants treated with buprenorphine had a 23-day length of treatment compared to 38 days for those treated with morphine (p=0.01). (Table 3 and Figure 2) This represents a 40% reduction. Length of stay in the buprenorphine group was reduced 24%, from 42 to 32 days (p=0.05). Three infants treated with buprenorphine required phenobarbital compared to one infant treated with morphine.

DISCUSSION

This study builds upon our prior report describing the use of buprenorphine in the treatment of opioid NAS. The goal of the current investigation was to optimize buprenorphine dosing by increasing the 1) initial dose, 2) rate of dose up-titration, and 3) maximum daily dose. An increase in
stock drug concentration was used to maintain manageable drug volume for administration. Sublingual buprenorphine continued to maintain safety at these higher doses. In addition, there was continued advantage over morphine in length of treatment and length of stay, which was now statistically significant. It is arguable that many signs and symptoms observed in the infant with CMV infection did not reflect severity of NAS but instead were manifestations of the multiorgan viral process. Data from this infant was included in the primary analysis. However, removal of this infant causes the length of treatment to drop from 23 to 21 days, and length of stay to drop from 32 to 26.

Three patients in the buprenorphine group required the use of adjunctive phenobarbital compared to one patient in the morphine group. Phenobarbital is often used as a rescue therapy when maximum opioid replacement therapy dose is reached without adequate resolution of symptoms. It has also been used as an initial adjunct in combination therapy with an opioid (12) or as initial monotherapy. (22) Morphine and buprenorphine employ different up-titration rates and number of up-titrations until maximum dose is reached (6 for buprenorphine and 9 for morphine). Thus, the need for adjunctive phenobarbital is not necessarily a surrogate of “treatment failure” in infants with a more severe withdrawal symptom complex. Phenobarbital arguably has a therapeutic index similar to that of opioid treatment in this patient population. It is also not clear where on the dose response curve the present maximum buprenorphine dose lies. Thus it is possible as a partial agonist, buprenorphine may not be able to induce the dense signal generation at the mu opioid receptor obtained with
morphine. Alternatively, it could be hypothesized that a higher maximum dose of buprenorphine could reduce the frequency with which adjunctive phenobarbital would need to be used. However, as there are no definitive adverse events associated with short-term exposure to phenobarbital, it is possible that a short course of phenobarbital may be a useful adjunct to reduce total duration of treatment in children with more severe withdrawal symptoms.

A mechanistic basis for the improvement of buprenorphine over morphine is not immediately clear. The longer duration of action and residence at the mu opioid receptor of buprenorphine relative to morphine may reduce the sudden shifts in receptor agonism and withdrawal symptoms. A more prolonged persistence of drug effect following cessation likely reduces symptoms. Two features of buprenorphine dosing compared to morphine also merit noting. Buprenorphine has a more rapid up-titration of dose compared to morphine, which may allow a quicker attainment of symptom control. Though both regimens employ a 10% weaning schedule, buprenorphine is stopped when a dose within 10% of the starting dose. In contrast, the initial morphine dose is 0.4 mg/kg/day, while cessation of dosing takes place only after drug has been weaned to 0.15 mg/kg/day. Finally, the buprenorphine group dosing was based upon birth weight, while the morphine group was dosed according to daily weight. This difference serves to decrease a relative dose of buprenorphine as the infant grows.

This study was of an open label, randomized, design with primary goals of demonstrating safety and feasibility of sublingual buprenorphine. It is possible
that there was occult bias in the scoring of infants by the nurse evaluators, despite the use of structured training sessions. A double blind, double dummy study would be required to fully evaluate any differential efficacy of buprenorphine over morphine. Another limitation is that the study excluded infants with benzodiazepine exposure and preterm infants. These exclusions serve to limit the generalizability of results. Infants with in utero benzodiazepine exposure have a longer length of stay and treatment compared to those without. These infants represent a group in whom research should be directed. Premature infants typically have less severe NAS, but buprenorphine does not have an established safety record in this population. Finally, while the length of treatment and length of stay noted is this study is consistent with observational data at Thomas Jefferson University Hospital between 2000-2006, it is longer than has been noted at other institutions. It is not clear if the magnitude of advantage over standard therapy would be maintained at institutions with a shorter length of stay.

In conclusion, buprenorphine at an optimized dose schema has been demonstrated to be safe and efficacious in the treatment of NAS. While indications of a therapeutic advantage over morphine again have been demonstrated, these need to be verified in a double blind clinical trial. Additionally, the unique characteristics of buprenorphine make exploration of outpatient use for treatment of NAS a ripe area for clinical research.

ACKNOWLEDGEMENTS
The authors would like to thank Linda Sailor and Rania Sadaka of the Thomas Jefferson University Hospital Investigational Drug Service, and the nurse practitioners and nurses of the Neonatal Intensive Care and Pediatric Care units.
<table>
<thead>
<tr>
<th></th>
<th>Morphine</th>
<th>Buprenorphine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>Male</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>8</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td>White, non Hispanic</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>African-American</td>
<td>1</td>
</tr>
<tr>
<td><strong>Birth weight (gm)</strong></td>
<td></td>
<td>3010</td>
</tr>
<tr>
<td><strong>Gestational Age (weeks)</strong></td>
<td>39.3</td>
<td>39.1</td>
</tr>
<tr>
<td><strong>Onset of Treatment. Mean Days after birth</strong></td>
<td>2.4 [SD 0.89]</td>
<td>2.3 [SD 1.4]</td>
</tr>
<tr>
<td><strong>1-Minute APGAR Score</strong></td>
<td>8.1</td>
<td>7.6</td>
</tr>
<tr>
<td><strong>5-Minute APGAR Score</strong></td>
<td>8.9</td>
<td>9.0</td>
</tr>
<tr>
<td><strong>Daily Maternal Methadone Dose (mg)</strong></td>
<td>124 [SD 60]</td>
<td>157 [SD 57]</td>
</tr>
</tbody>
</table>

II Mean
Table 2: Efficacy Outcomes of Buprenorphine and Neonatal Opium Solution Mean

<table>
<thead>
<tr>
<th></th>
<th>Buprenorphine</th>
<th>Morphine</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>12</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Length of Treatment (days)</td>
<td>23 [SD 12]</td>
<td>38 [SD 14]</td>
<td>0.01</td>
</tr>
<tr>
<td>Length of Stay (days)</td>
<td>32 [SD 24]</td>
<td>42 [SD 13]</td>
<td>0.05</td>
</tr>
<tr>
<td>Phenobarbital adjunctive</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>therapy (patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subject Allocation Number</td>
<td>Treatment</td>
<td>Adverse Event</td>
<td>Serious AE</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------</td>
<td>--------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>039 morphine</td>
<td>oral thrush</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>paronychia of finger</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td>047 buprenorphine</td>
<td>reflux/poor feeding</td>
<td>yes probably not related</td>
<td></td>
</tr>
<tr>
<td></td>
<td>elevated transaminases</td>
<td>no probably not related</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cytomegalovirus infection</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>aminoaciduria</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td>049 morphine</td>
<td>conjunctivitis</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td>050 morphine</td>
<td>oral thrush</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td>051 buprenorphine</td>
<td>clavicle birth fracture</td>
<td>no unrelated</td>
<td></td>
</tr>
<tr>
<td>052 morphine</td>
<td>reflux</td>
<td>no unrelated</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1: Study Schema

Screening

**Inclusion**
- $\geq 37$ weeks gestation
- In utero exposure to opioids
- Need for pharmacologic therapy for NAS

**Exclusion**
- Exposure to benzodiazepines
- Medical illness
- Breastfeeding

Randomization

- **Buprenorphine 15.9 mcg/kg in 3 divided doses**
  - Increase dose 25% until symptoms controlled
  - Phenobarbital added when dose reaches 60 mcg/kg/day

  **Wean dose 10% per day as tolerated**

  **Cessation of therapy when within 10% of initial dose**

- **Morphine 0.4 mg/kg/day in 6 divided doses**
  - Increase dose 10% until symptoms controlled
  - Phenobarbital added when dose reaches 1 mg/kg/day

  **Wean dose 10% per day as tolerated**

  **Cessation of therapy at 0.15 mg/kg/day**

2 days observation prior to discharge
Figure 2: Length of Treatment and Length of Stay

Length Of Treatment, Morphine Solution Compared to Buprenorphine

Length of Stay, Morphine Solution Compared to Buprenorphine

p value = 0.01

p value = 0.05